Enrolling By Invitation OBSERVATIONAL NCT04824040

Clinical, Immunological, Morphological and Genetic Characteristics of Patients With Dysferlinopathy (LGMD R2) in the RF (DYSF-RUS)

Evaluation of Clinical, Immunological, Morphological, Molecular and Genetic Characteristics of Patients With Limb-girdle Muscular Dystrophy Type R2 (Type 2B) in the Russian Federation

Sponsor: Artgen Biotech

Conditions DMAT Dysferlinopathy LGMDR2 Miyoshi Myopathy

Updated 8 times since 2021 Last updated: Jun 24, 2025 Started: Jan 15, 2020 Primary completion: Feb 25, 2027 Completion: Jul 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on DMAT and Dysferlinopathy, this trial is ongoing. The trial is conducted by Artgen Biotech and has accumulated 8 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Enrolling By Invitation
Jul 2025 — Sep 2025 [monthly]

Enrolling By Invitation

Status: Unknown → Enrolling By Invitation
Sep 2024 — Jul 2025 [monthly]

Unknown
Aug 2024 — Sep 2024 [monthly]

Unknown

Status: Enrolling By Invitation → Unknown
Jul 2024 — Aug 2024 [monthly]

Enrolling By Invitation

▶ Show 3 earlier versions

Sep 2022 — Jul 2024 [monthly]

Enrolling By Invitation
Dec 2021 — Sep 2022 [monthly]

Enrolling By Invitation
May 2021 — Dec 2021 [monthly]

Enrolling By Invitation

First recorded

Jan 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Artgen Biotech
Genotarget

Data source: Artgen Biotech

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Moscow, Russia